- Home
- EVT vs NVCR Comparison
EVT vs NVCR Comparison
Compare EVT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVT | NVCR |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EVT | NVCR |
|---|---|---|
| Price | $27.53 | $16.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 105.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $23.00 | $9.82 |
| 52 Week High | $27.96 | $18.92 |
Technical Indicators
Market Signals| Indicator | EVT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 50.50 |
| Support Level | $25.66 | $12.49 |
| Resistance Level | $27.96 | $18.59 |
| Average True Range (ATR) | 0.46 | 0.92 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 74.25 | 65.48 |
Price Performance
Historical ComparisonAbout EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.